Immunity & Ageing (Oct 2012)

CMV and Immunosenescence: from basics to clinics

  • Solana Rafael,
  • Tarazona Raquel,
  • Aiello Allison E,
  • Akbar Arne N,
  • Appay Victor,
  • Beswick Mark,
  • Bosch Jos A,
  • Campos Carmen,
  • Cantisán Sara,
  • Cicin-Sain Luka,
  • Derhovanessian Evelyna,
  • Ferrando-Martínez Sara,
  • Frasca Daniela,
  • Fulöp Tamas,
  • Govind Sheila,
  • Grubeck-Loebenstein Beatrix,
  • Hill Ann,
  • Hurme Mikko,
  • Kern Florian,
  • Larbi Anis,
  • López-Botet Miguel,
  • Maier Andrea B,
  • McElhaney Janet E,
  • Moss Paul,
  • Naumova Elissaveta,
  • Nikolich-Zugich Janko,
  • Pera Alejandra,
  • Rector Jerrald L,
  • Riddell Natalie,
  • Sanchez-Correa Beatriz,
  • Sansoni Paolo,
  • Sauce Delphine,
  • van Lier Rene,
  • Wang George C,
  • Wills Mark R,
  • Zieliński Maciej,
  • Pawelec Graham

DOI
https://doi.org/10.1186/1742-4933-9-23
Journal volume & issue
Vol. 9, no. 1
p. 23

Abstract

Read online

Abstract Alone among herpesviruses, persistent Cytomegalovirus (CMV) markedly alters the numbers and proportions of peripheral immune cells in infected-vs-uninfected people. Because the rate of CMV infection increases with age in most countries, it has been suggested that it drives or at least exacerbates “immunosenescence”. This contention remains controversial and was the primary subject of the Third International Workshop on CMV & Immunosenescence which was held in Cordoba, Spain, 15-16th March, 2012. Discussions focused on several main themes including the effects of CMV on adaptive immunity and immunosenescence, characterization of CMV-specific T cells, impact of CMV infection and ageing on innate immunity, and finally, most important, the clinical implications of immunosenescence and CMV infection. Here we summarize the major findings of this workshop.